BridgeMD
New treatment option for Recurrent High Grade Glioma
Official title Recurrent High Grade Glioma Treated by LITT
ClinicalTrials.gov ID: NCT06161610
What this study is testing
- What it's testing
- This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients. The main questions it aims to answer are: The LITT would increase the progression-free survival and overall survival of rHGG patients compared to other treatments.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged 18 years old or above;
- Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or...
- Meet any of the following:
- Meets the disease progression criteria in the Response Evaluation of Neuro-Oncology (RANO 2.0) criteria;
- At least one image other than T1 contrast indicates progression;
You likely can't join if
- Patients may benefit from other treatments or may not benefit from this trial;
- No more than three months since the patient underwent craniotomy;
- MRI contrast cannot be performed;
- Severe coagulation disorder;
- Women who are pregnant, lactating, or planning to become pregnant within 6 months;
- Participated in any other clinical trials of drugs or medical devices within 3 months;
See the full eligibility criteria
- Aged 18 years old or above;
- Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment;
- Meet any of the following:
- Meets the disease progression criteria in the Response Evaluation of Neuro-Oncology (RANO 2.0) criteria;
- At least one image other than T1 contrast indicates progression;
- Pathology shows progression or recurrence;
- Other progress determined by the Clinical Events Committee (CEC);
- All tumor lesions are located supratentorial and the maximum cross-sectional short-axis length in the T1 contrast is ≤30 mm;
- Karnofsky score (KPS) ≥ 60 and the patient can tolerate the intervention;
- The people or their agent can understand the purpose of the trial, show sufficient compliance with the trial protocol, and sign the informed consent form.
- Patients may benefit from other treatments or may not benefit from this trial;
- No more than three months since the patient underwent craniotomy;
- MRI contrast cannot be performed;
- Severe coagulation disorder;
- Women who are pregnant, lactating, or planning to become pregnant within 6 months;
- Participated in any other clinical trials of drugs or medical devices within 3 months;
- Combined diseases that may interfere with treatment or prognosis assessment;
- Refuse or unlikely to complete follow-up assessment;
- Other circumstances in which the researcher deems it inappropriate to participate in this clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Guangzhou, Guangdong, China
- Zhengzhou, Henan, China
- Wuhan, Hubei, China
- Changchun, Jilin, China
- Shenyang, Liaoning, China
- Jinan, Shandong, China
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Guangzhou, Guangdong, China; Zhengzhou, Henan, China; Wuhan, Hubei, China; Changchun, Jilin, China; Shenyang, Liaoning, China and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.